Cantor Fitzgerald initiated coverage of Veradermics with a rating of Overweight

Jefferies initiated coverage of Veradermics with a rating of Buy and set a new price target of $75.00

Citigroup initiated coverage of Veradermics with a rating of Buy and set a new price target of $85.00

Leerink Partners initiated coverage of Veradermics with a rating of Outperform and set a new price target of $75.00

4/A - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

3 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

Enrollment completed in two pivotal trials of VDPHL01 in male patients; topline data expected from Study 302 in 1H 2026 and Study 304 confirmatory trial in 2H 2026 Enrollment on-track in Study 306, the first-ever Phase 2/3 trial of an oral treatment specifically for female pattern hair loss Mark Neumann, seasoned biopharmaceutical commercial leader with more than 30 years of experience launching and scaling blockbuster therapies, appointed Chief Commercial and Strategy Officer Upsized IPO of $294.8 million closed in February 2026; pro forma cash, cash equivalents and marketable securities expected to fund planned operations into 2029, through multiple anticipated Phase 3 readouts and

Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that three abstracts will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting being held in Denver, Colorado on March 27 – 31, 2026. The data to be presented include a blinded, retrospective investigator global assessment conducted by six independent dermatologists regarding the comparative perceived efficacy of VDPHL01 versus existing minoxidil formulations and the clinical potential of VDPHL01. In addition, two presentations will characteriz

Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that management will participate in the following upcoming investor conferences in March: Leerink Partners Global Healthcare Conference on Tuesday, March 10 in Miami, FL Reid Waldman, M.D., CEO of Veradermics, will participate in a fireside chat at 4:20 p.m. ET. Jefferies Biotech on the Beach Summit on Wednesday, March 11 in Miami, FL A live webcast of the Leerink conference fireside chat will be available on the "Events" page of the "Investors" section of the

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 12, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on February 12th Markets are higher after mixed reactions to yesterday's hotter than expected Jobs Report as the Bureau of Labor Statistics reported that the U.S. economy added 130,000 jobs.Forgent Power Solutions (NYSE:FPS) is celebrating its early February IPO this morning with shares having jumped 22% since trading

This marks the completion of enrollment of all male Phase 3 studies of VDPHL01 in pattern hair loss, with approximately 1,000 male patients enrolled across studies Topline data from initial '302' trial anticipated in the first half of 2026; '304' confirmatory study topline data anticipated in the second half of 2026 VDPHL01, if approved, has the potential to be the first and only non-hormonal oral FDA approved treatment for men and women with pattern hair loss, a condition affecting an estimated 50 million men and 30 million women in the United States Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing

Veradermics, Incorporated ("Veradermics"), (NYSE:MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the closing of its previously announced upsized initial public offering of 17,339,294 shares of its common stock at an initial public offering price of $17.00 per share, including 2,261,647 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. The gross proceeds from the offering were approximately $294.8 million, before deducting underwriting discount and commissions and estimated offering expenses. All o